#bioADM

Adjustment of the SMART risk score by bioactive adrenomedullin enables a more accurate prediction of mortality in patients with ASCVD Bioactive adrenomedullin 1-52 (bio-ADM) is a novel biomarker for the assessment of endothelial function and prediction of adverse outcomes in patients with acute heart failure and cardiogenic shock. T...

Excited to share our new paper is now out in #Atherosclerosis:
In patients with #ASCVD, adding #bioADM to the ESC-recommended #SMART risk score improves risk prediction and model performance.

Thanks to all collaborators for the joint effort.

Read here (open access): tinyurl.com/3jtdhpzv